Aquestive Therapeutics, headquartered in Warren, New Jersey, develops differentiated pharmaceutical products for unmet medical needs, including severe allergic reactions and CNS diseases, using its proprietary PharmFilm technology. The company's portfolio includes Anaphylm and Libervant, with an IPO launched on July 25, 2018.
Ken W Marshall bought 1,445 shares of AQST on 21 November at $10.15 per share, worth a total of $15K. They now own 1,445 AQST shares.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.